Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT01434472 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01434472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01434472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
November 16, 2011
Completion date
May 6, 2020
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-transplant lymphoproliferative disorder, recurrent adult diffuse large cell lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent burkitt lymphoma, refractory b-cell non-hodgkin lymphoma, refractory burkitt lymphoma, refractory diffuse large b-cell lymphoma